The therapy, dubbed OST-HER2, uses a HER2-bioengineered form of the bacteria Listeria monocytogenes to trigger an immune ...

A month after halting dosing in two of the three treatment arms of a phase 2 trial of its pulmonary arterial hypertension ...

GE HealthCare is launching a new imaging research collaboration with the University of California, San Francisco, aimed at ...

Neumora Therapeutics’ phase 3 fail was worse than analysts feared. | Neumora Therapeutics’ phase 3 fail was worse than ...

The FDA is elevating a recall from Philips related to one of its wearable outpatient heart monitors, used to help detect ...

Yesterday, spots of pink could be spotted on the streets of San Francisco, and it wasn’t a coincidence. Members of the ...

And while Wood said the pharma still isn’t interested in joining the overcrowded obesity landscape, GSK is considering ways ...

Welcome to Day 2 of the J.P. Morgan Healthcare Conference 2025 in San Francisco. | Welcome to Day 2 of the J.P. Morgan ...

With an FDA approval submission for RegenXBio’s Hunter syndrome gene therapy already underway, the biopharma has now ...

N-Power Medicine, a tech firm with a clinical trial platform for capturing real-world patient data, has acquired precision ...

Illumina and Regeneron are taking stakes in health data company Truveta to help fund research that may dwarf the efforts of ...

Umoja Biopharma has secured $100 million in series C funds as the cancer-focused biotech looks to bring more of its cell ...